PR88028

HAIFA, Israel and MIAMI, Feb. 10, 2021 /PRNewswire=KYODO JBN/ --

- Insightec is strategically positioned for expansion in the China market

Insightec(R) [http://www.insightec.com], a global healthcare company focused on

creating the next generation of patient care, announced it received market

approval by The National Medical Products Administration (NMPA), the Chinese

agency for regulating drugs and medical devices (formerly the China Food and

Drug Administration, or CFDA).

The approval for the Exablate(R) 4000 (Exablate Neuro) platform, will enable

unilateral Focused Ultrasound treatment for patients living with debilitating

tremor from Essential Tremor and Tremor-dominant Parkinson's Disease that has

not responded to medications.  

"This achievement reflects positive momentum to bring Focused Ultrasound to

movement disorder patients in China," commented Maurice R. Ferré MD, Insightec

CEO and Chair of the Board of Directors. "We are committed to improving the

quality of life of patients in China and worldwide with impactful therapeutic

treatments."

MR-guided Focused Ultrasound (MRgFUS), also referred to as high-intensity

Focused Ultrasound, delivers acoustic energy precisely to the Vim of the

thalamus, considered to be responsible for tremor, to heat and ablate the

tissue. The procedure does not require surgical incisions, implants or

anesthesia.

Nearly 60 leading neurosurgeons in medical centers around the globe are

treating patients with hand tremor from Essential Tremor or Tremor-dominant

Parkinson's Disease on a regular basis with the Exablate Neuro. Performed in a

single session in an MRI suite, many patients experience immediate tremor

relief with minimal side effects, returning home the same day.

"There are millions of people in China living with diminished function due to

hand tremors from Essential Tremor and Tremor-dominant Parkinson's Disease,"

said Peng Qiu, Insightec China Country Manager. "Our elderly communities will

now have an option that uses highly advanced technology that is less invasive."

Exablate Neuro has received marketing approval for Essential Tremor from the

U.S. Food and Drug Administration (FDA) and regulatory bodies in Argentina,

Australia, Canada, Chile, Europe, Israel, Japan, Kazakhstan, Korea, Russia,

Taiwan and Turkey.

Insightec's Exablate Body system is used in 20 hospitals across China to treat

symptomatic uterine fibroids.

About Insightec

Insightec is a global healthcare company creating the next generation of

patient care by realizing the therapeutic power of acoustic energy. The

company's Exablate® Neuro platform uses Focused Ultrasound, guided by MRI, to

provide tremor relief to patients with Essential Tremor and Tremor-Dominant

Parkinson's Disease. Research for future applications in the neuroscience space

is underway in partnership with leading academic and medical institutions.

Insightec is headquartered in Haifa, Israel, and Miami, with offices in Dallas,

Shanghai and Tokyo. For more information, please visit: www.insightec.com.

Forward-looking Statements

This document contains forward-looking statements regarding, among other

things, plans, expectations, and future events. In some cases, forward-looking

statements can be identified by the following words: "may," "can," "will,"

"could," "would," "should," "expect," "intend," "plan," "anticipate,"

"believe," "estimate," "predict," "project," "potential," "promise,"

"continue," "ongoing," or the negative of these terms. Forward-looking

statements involve known and unknown risks, uncertainties and other important

factors that could cause actual results to differ materially from what is

expressed or implied by the statements. Any forward-looking statement is based

on information available to INSIGHTEC as of the date of the statement. All

written or oral forward-looking statements attributable to INSIGHTEC are

qualified by this caution. INSIGHTEC does not undertake any obligation to

update or revise any forward-looking statement to reflect any change in

circumstances or in INSIGHTEC's expectations.

"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether

standing alone or in connection with the word " INSIGHTEC," are protected

trademarks of INSIGHTEC.

Logo - https://mma.prnewswire.com/media/1120780/Insightec_Logo.jpg

Source: Insightec